How We’re Mobilizing Our Resources to Help Find Solutions for COVID-19
Learn More
Share
Janssen
As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.
As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
From scientists working on a potential vaccine to medically trained employees who mobilized to the front lines to help treat patients, these men and women share what most resonates for them about the unique and devastating virus, both professionally and personally.
Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.
Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
Check out this infographic breakdown of the company’s first-quarter 2020 performance, with key highlights from its pharmaceutical, consumer and medical devices businesses.
Cardiologist C. Michael Gibson is heading up a virtual research study that uses wearable technology and cutting-edge apps to help detect atrial fibrillation, one of the biggest risk factors for stroke. We dive into how the study will work.
From a donation of a million masks to help protect vulnerable healthcare workers to committed research on a potential vaccine, the company has activated quickly in several key ways to help address the outbreak.
The coronavirus has made headlines as it has spread from China to other parts of the world. To help stop the global outbreak in its tracks, Johnson & Johnson is already hard at work on a potential preventive vaccine.
Check out this infographic breakdown of the company’s fourth quarter and annual earnings report, with key performance highlights from its pharmaceutical, consumer and medical devices businesses.
Innovativeness and a commitment to social responsibility are just some of the respected attributes that helped the company land on the prestigious list for another year.
It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.
From robotics solutions for orthopedic surgery to the potential to bring new hope to patients living with multiple myeloma through CAR-T, these are just some of the cutting-edge projects that these visionaries think could potentially help propel healthcare forward around the globe.
A groundbreaking trial for an HIV vaccine. New ways to help the body heal itself. Immunotherapy treatments for cancer. Behind medical advancements like these are the brilliant scientists who are relentlessly pushing their visions and research forward.
From a first-of-its-kind contact lens that darkens when exposed to bright light to the first donation of 500,000 doses of an Ebola vaccine, here are just some of the ways Johnson & Johnson helped change the trajectory of health for humanity this past year.
